SecBot SecBot
SECBOTREPLAY Home › Report › KYMR

KYMR · Kymera presented Phase 1 data for KT-621 (oral STAT6 degrader) in…

Kymera Therapeutics, Inc. · PRESS-RELEASE filed Jun 12, 2026 at 07:00 ET

At the news

NEUTRALIMPACT 3/10

PRESS-RELEASE filed Jun 12, 2026 at 07:00 ET

Kymera presented Phase 1 data for KT-621 (oral STAT6 degrader) in healthy Japanese adults at the JDA Annual Meeting, showing safety and PK/PD results consistent with prior studies. The data supports global Phase 2b trials (BROADEN2 in atopic dermatitis, BREADTH in asthma) that are ongoing with readouts expected by mid-2027 and late 2027, respectively. This is an incremental data update with no new efficacy or regulatory catalyst, a routine clinical-stage update for a $6.8B biotech.

  • Phase 1 study in 24 healthy Japanese adults showed median STAT6 degradation ≥98% at both dose levels at Day 7, consistent with prior non-Japanese studies.
  • KT-621 was well tolerated with a favorable safety profile across both doses.
  • Parallel Phase 2b trials BROADEN2 (atopic dermatitis) and BREADTH (asthma) are ongoing; data expected by mid-2027 and late 2027, respectively.
  • No new efficacy data, regulatory milestone, or financial guidance was disclosed in this press release.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access